On December 18, 2025, the White House issued an order to enhance research and access to medical marijuana and cannabidiol (CBD). This decision followed an FDA review that recognized medical uses for marijuana, particularly for managing pain, nausea, and specific chronic conditions. The recommendation to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act aims to facilitate research and ensure that patients have access to safer, regulated products.

Currently, many patients rely on medical marijuana for relief from chronic pain, with significant usage noted among seniors and veterans. The article emphasizes that the Federal Government’s previous stance has hindered essential research required for understanding the efficacy and safety of medical marijuana and CBD products. By updating the legal framework and collaborating with Congress, the administration plans to provide clearer guidelines and enhance patient safety through better-informed healthcare practices.

Additionally, the order outlines the responsibilities of various federal agencies to develop research methods that utilize real-world evidence while ensuring appropriate regulations surrounding hemp-derived cannabinoid products. This initiative seeks to address existing gaps in knowledge regarding the health impacts of marijuana and CBD, particularly for specific populations such as adolescents and individuals with chronic health issues. Overall, the White House intends to close the knowledge gap and increase access to effective health solutions for Americans.

Original: article